The clinical story of GLP-1 receptor agonist medications has evolved dramatically over the past decade. Initially developed as glucose-lowering agents for type 2 diabetes, these medications — including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — have demonstrated a remarkable range of systemic benefits that extend far beyond weight reduction and glycemic control. Long-term outcomes trial data now confirm significant and clinically meaningful reductions in major cardiovascular events, chronic kidney disease progression, and other chronic diseases. Understanding these benefits reframes GLP-1 RA therapy from a “weight loss drug” to a comprehensive cardiometabolic disease-modifying treatment.
The SELECT Trial: Cardiovascular Protection Without Diabetes
The most landmark recent trial in this space is the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity), published in the New England Journal of Medicine in 2023 (Lincoff AM, et al.).
Trial design: SELECT enrolled 17,604 adults with pre-existing cardiovascular disease (prior myocardial infarction, stroke, or peripheral arterial disease), a BMI of at least 27 kg/m², but without type 2 diabetes. Participants were randomized to semaglutide 2.4 mg once weekly (Wegovy dose) or placebo in addition to standard of care, and followed for up to 5 years.
Primary outcome: Major adverse cardiovascular events (MACE) — the composite of cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke.
Result: Semaglutide 2.4 mg reduced the risk of MACE by 20% compared to placebo (HR 0.80, 95% CI 0.72–0.90; p<0.001). This absolute risk reduction translated to 1.5 fewer events per 100 patients over a median follow-up of approximately 40 months.
Why this is landmark: Prior cardiovascular outcomes trials with GLP-1 RA (SUSTAIN-6, LEADER) demonstrated CV benefit primarily in patients with type 2 diabetes. SELECT was the first trial to demonstrate cardiovascular benefit in patients without diabetes — a population in whom obesity itself, independent of glucose metabolism, drives cardiovascular risk. This established GLP-1 RA as a cardiovascular disease-modifying therapy beyond the diabetes context.
Based on the SELECT trial, the FDA granted Wegovy an additional indication: reduction of cardiovascular events in adults with established CVD and obesity or overweight. This has important implications for insurance coverage — see GLP-1 RA Cost and Insurance Coverage.
Mechanisms of Cardiovascular Benefit
The cardiovascular benefits of GLP-1 RA are likely multifactorial and not solely attributable to weight loss:
- Anti-inflammatory effects: GLP-1 receptors are expressed on immune cells, endothelial cells, and macrophages. GLP-1 RA reduces circulating markers of systemic inflammation including C-reactive protein (CRP) and interleukins, which drive atherosclerotic plaque progression.
- Direct cardiac effects: GLP-1 receptors are expressed in cardiac myocytes and vascular smooth muscle. GLP-1 RA may improve myocardial function, reduce cardiac remodeling after ischemia, and improve endothelial vasodilatory responses.
- Blood pressure reduction: GLP-1 RA consistently reduces systolic blood pressure by 3–5 mmHg — a meaningful cardiovascular risk reduction contribution.
- Lipid improvements: Modest reductions in triglycerides and LDL-cholesterol are observed, alongside improvements in HDL.
- Weight loss contribution: The substantial weight reduction achieved with GLP-1 RA also contributes to long-term cardiovascular risk reduction through multiple pathways, including improvements in insulin sensitivity, blood pressure, and lipid profiles.
💡 💡 Clinical Pearl: Early vs. Late Cardiovascular Benefit
An interesting feature of the SELECT trial results is that cardiovascular event reduction appeared relatively early — within the first 3–4 months of treatment — before substantial weight loss had occurred. This early benefit is thought to reflect anti-inflammatory and direct vascular effects of GLP-1 receptor activation, independent of weight reduction. This finding supports the idea that GLP-1 RA has intrinsic cardioprotective properties beyond its role as a weight-loss agent — making it a genuinely disease-modifying cardiovascular therapy.
The FLOW Trial: Kidney Protection in Type 2 Diabetes and CKD
The FLOW trial (Semaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease), published in the New England Journal of Medicine in 2024 (Perkovic V, et al.), provides landmark evidence for the renal benefits of semaglutide.
Trial design: FLOW enrolled 3,533 patients with type 2 diabetes and chronic kidney disease (CKD stages 2–4, with significant proteinuria). Participants received semaglutide 1 mg once weekly or placebo, added to standard CKD and diabetes management (including RAAS inhibitors and SGLT2 inhibitors where appropriate).
Primary outcome: A composite of kidney failure, a sustained 50% reduction in eGFR, death from kidney disease, or death from cardiovascular disease.
Result: Semaglutide reduced the risk of the primary composite kidney outcome by 24% compared to placebo (HR 0.76, 95% CI 0.66–0.88; p<0.001). The trial was stopped early due to overwhelming efficacy. Additionally, semaglutide reduced cardiovascular death in this high-risk population.
Clinical significance: CKD affects approximately 37 million Americans and is a leading cause of end-stage renal disease. Before FLOW, SGLT2 inhibitors were the primary pharmacological strategy for CKD progression in diabetic patients. FLOW establishes semaglutide as an additional disease-modifying option in this context, with benefits seen on top of optimized RAAS and SGLT2 inhibitor therapy.
Emerging Evidence: Beyond Cardiovascular and Renal Benefits
Ongoing research is exploring GLP-1 RA benefits across numerous other chronic disease domains:
- Metabolic dysfunction-associated steatotic liver disease (MASLD/MASH): Multiple trials (including ESSENCE with semaglutide) have shown significant reduction in liver fat and histological improvement in MASH, with semaglutide receiving regulatory approval for this indication in some markets.
- Sleep apnea: The SURMOUNT-OSA trial (2024) demonstrated that tirzepatide significantly reduced sleep apnea severity (AHI) in patients with obesity-related obstructive sleep apnea, leading to FDA approval of this indication for Zepbound.
- Neurodegenerative disease: Preclinical data and emerging human observational studies suggest potential neuroprotective effects of GLP-1 RA, with trials underway in Alzheimer’s disease and Parkinson’s disease.
- Alcohol and addiction: Observational and early trial data suggest GLP-1 RA may reduce alcohol cravings and consumption, with implications for alcohol use disorder treatment.
- Cancer risk reduction: Large observational studies have suggested reduced rates of certain obesity-related cancers in GLP-1 RA users, though causality and mechanism require further prospective study.
Long-Term Safety and Monitoring
With long-term GLP-1 RA use, patients and clinicians should maintain awareness of safety considerations discussed throughout this article series, including thyroid monitoring (see Thyroid Cancer Risk and GLP-1 RA), pancreatitis awareness, and the need for continued lifestyle support (see Nutrition on GLP-1 RA and Exercise on GLP-1 RA). The weight regain following discontinuation, documented in the STEP 4 trial, provides strong evidence for the importance of indefinite therapy in most patients — as reviewed in Weight Regain After Stopping GLP-1 RA.
Regular monitoring should include: HbA1c and fasting glucose (for diabetic patients), blood pressure, lipid panel, renal function (eGFR, urinary albumin-to-creatinine ratio in CKD patients), thyroid function where clinically indicated, and weight and body composition assessments.
💡 Frequently Asked Questions (FAQ)
Q1: If I don’t have diabetes, can I still benefit from semaglutide for heart protection?
A1: Yes. The SELECT trial specifically enrolled patients without diabetes and demonstrated a 20% reduction in major cardiovascular events. If you have established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) and obesity or overweight, you may be a candidate for Wegovy under the cardiovascular risk reduction indication — discuss this with your cardiologist or primary care physician.
Q2: Do GLP-1 RA medications protect the kidneys even without diabetes?
A2: The FLOW trial focused on patients with type 2 diabetes and CKD. Some cardiovascular trials including SELECT showed eGFR-preserving effects in mixed populations. Research on GLP-1 RA renal benefits in non-diabetic CKD is ongoing, but current evidence for kidney protection is strongest in the type 2 diabetes and CKD context.
Q3: Should I expect to stay on GLP-1 RA for the rest of my life?
A3: For patients with established cardiovascular disease, type 2 diabetes, or CKD, long-term or indefinite GLP-1 RA therapy is generally the most evidence-based approach given the documented disease-modifying cardiovascular and renal benefits. For weight management alone, the decision is more individualized and depends on weight maintenance success, tolerance, and access considerations.
📚 References & Sources
- Lincoff, A.M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine, 389(24), 2221–2232.
- Perkovic, V., et al. (2024). Semaglutide in patients with type 2 diabetes and chronic kidney disease (FLOW trial). New England Journal of Medicine, 391(2), 109–121.
- Rubino, D.M., et al. (2022). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA, 327(14), 1414–1425.